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Background. Gp91
phox is a transmembrane protein and the catalytic core of the NADPH oxidase complex of neutrophils. Lack
of this protein causes chronic granulomatous disease (CGD), a rare genetic disorder characterized by severe and recurrent
infections due to the incapacity of phagocytes to kill microorganisms. Methodology. Here we optimize a prokaryotic cell-free
expression system to produce integral mammalian membrane proteins. Conclusions. Using this system, we over-express
truncated forms of the gp91
phox protein under soluble form in the presence of detergents or lipids resulting in active proteins
with a ‘‘native-like’’ conformation. All the proteins exhibit diaphorase activity in the presence of cytosolic factors (p67
phox,
p47
phox, p40
phox and Rac) and arachidonic acid. We also produce proteoliposomes containing gp91
phox protein and
demonstrate that these proteins exhibit activities similar to their cellular counterpart. The proteoliposomes induce rapid
cellular delivery and relocation of recombinant gp91
phox proteins to the plasma membrane. Our data support the concept of
cell-free expression technology for producing recombinant proteoliposomes and their use for functional and structural studies
or protein therapy by complementing deficient cells in gp91
phox protein.
Citation: Marques B, Liguori L, Paclet M-H, Villegas-Mende ´z A, Rothe R, et al (2007) Liposome-Mediated Cellular Delivery of Active gp91
phox. PLoS
ONE 2(9): e856. doi:10.1371/journal.pone.0000856
INTRODUCTION
Gp91
phox protein is the catalytic subunit of the NADPH oxidase
complex in human neutrophils and is involved in the electron
transfer from NADPH to molecular oxygen O2 [1]. Gp91
phox is
a transmembrane glycoprotein which physiologically associates
with the p22
phox subunit to form flavocytochrome b558 [2].
MALDI and nanospray LC-MS/MS methods have delineated the
transmembrane domains of gp91
phox [3]. This protein contains six
putative a-helices and three extracellular loops in which the
glycosylation sites (Asn132, Asn149 and Asn240) are comprised in
loops 2 and 3 [4]. In its active state, NADPH oxidase is a multi-
component enzyme complex composed of cytochrome b558
(gp91
phox and p22
phox) and cytosolic factors (p67
phox, p47
phox,
p40
phox, Rac and Rap1A) that translocate at the membrane
surface from cytosol upon stimulation. From this transfer and
through the assembly of the constituents, NADPH oxidase is
activated [5]. Upon infection or stimulation with inflammatory
mediators, NADPH oxidase from neutrophils generate O2
2 and
then oxygen derivatives, or ROS, which are necessary for the
defense of the organism.
Recent studies on the C-terminal part (amino acids 221 to 570)
of gp91
phox protein show that the cytoplasmic domain retains
a high NADPH diaphorase activity [6] that can be stimulated in
the presence of cytosolic proteins Rac and p67
phox. This supports
the hypothesis that p67
phox and Rac bind directly to gp91
phox and
activates NADPH oxidase by inducing conformational changes in
its flavoprotein domain [7]. Using a similar approach, different
domains of p22
phox protein have been delineated and shown to be
involved in the maturation of the gp91
phox protein before the
assembly of the gp91
phox/p22
phox heterodimer [8].
Among these approaches, an internal domain in the N-terminal
part of p22
phox is involved in the flavocytochrome assembly,
whereas the proline-rich region (PRR motif) in the C-terminal
portion is responsible for NADPH oxidase activity via the binding
to the p47
phox SH3 domain [1].
Chronic granulomatous disease (CGD) is a rare immuno-
deficiency disease caused by mutations in genes encoding one of
the main constituents of NADPH oxidase [9]. Mutations in the
CYBB gene encoding gp91
phox represent almost 60% of CGD
cases. These defects largely result in a lack of protein expression
(Xu CGD) or, in less than 10% of CGD cases, in a decrease or
a loss of oxidase activity while protein is present (X
2 or X
+ CGD).
Recently, gene therapy has been tested in animal models and in
clinical trials to attempt to reconstitute NADPH oxidase activity in
X-linked CGD mice or in X-linked CGD patients [10]. Although
promising results have been reported, this method still employs
a retrovirus that may deliver the corrective gene into the patient’s
genome in locations which affect essential genes such as those
involved in cancer.
Beside gene therapy, recent progress has been made with
methods for the delivery of functional proteins which are based on
the direct delivery of active therapeutic proteins into targeted
living cells or, in the case of monoclonal antibodies, for the
stimulation of specific immune responses [11]. Different strategies
are used for the delivery of functional proteins such as micro-
injection, electroporation, liposomes or by fusion to a protein
transduction domain (PTD). Among these delivery systems,
liposomes represent a promising technology for the delivery of
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non-cytotoxic; (2), they can deliver and specifically target a large
set of bioactive molecules (such as proteins, DNA or ribozymes);
(3), they can protect molecules from degradation; and (4), their
composition is easily modifiable. Different studies have used
liposomes for the delivery of proteins such as antigens or toxins,
drugs and nucleic molecules, but none of them has attempted to
deliver membrane proteins.
The production of recombinant membrane proteins by the
classical overexpression systems still presents a technical challenge.
Among these challenges are yield, correct folding, solubility and
protein integration into the lipid membrane to constitute
functional proteoliposomes [12]. However, due to their hydro-
phobic nature, it is difficult to make membrane proteins in a native
conformation for functional and structural studies in these in vivo
systems. An interesting and attractive alternative for producing
membrane proteins is the use of cell-free transcription/translation
systems. These cell-free protein synthesis systems are essentially
derived from rabbit reticulocytes, Escherichia coli lysates, or wheat
germ [13]. One of the advantages of these in vitro expression
systems is their capability to synthesize cytotoxic membrane
proteins, or regulatory or unstable proteins that cannot be
expressed in living organisms. The efficient expression of integral
membrane proteins from prokaryotic sources has recently been
demonstrated by using optimized E. coli cell-free systems [14]. The
modification of the reaction conditions by adding chaperones,
detergents or E. coli lipids have improved the synthesis and solubility
of the expressed membrane proteins. Furthermore, solubilization of
precipitated membrane proteins from cell-free expression systems
and the integration into synthetic lipid vesicles result in the
production of functional proteoliposomes [15]. A similar approach
has been attempted in the production of functional mammalian
membrane proteins, G protein coupled receptors (GPCRs) [16].
Three human GPCRs were synthesized by an E. coli cell-free
expression system as fusion proteins with a thioredoxin tag. After
integration into phospholipid vesicles, these GPCRs proteins
displayed ligand-binding activities. However, the formation of
functional proteoliposomes containing GPCRs with this technology
requires first solubilization in the presence of detergents, and then
reconstitution into lipid vesicles through long-term dialysis. Even if
this work represents an important advance in the synthesis of
mammalian membrane proteins by cell-free expression technology,
it cannot be applied as a general strategy for producing membrane
proteins due to the large size of the thioredoxin tag (11.2kDa), which
may impair the protein activity.
In this study, we assessed the potential of the cell-free expression
system to synthesize functional truncated forms of the gp91
phox
subunit and its capacity to directly produce proteoliposomes
containing these truncated forms. We demonstrate that all the
truncated forms are expressed as soluble proteins in the presence
of detergents and display fully enzymatic activity. Moreover, the
addition of natural lipid vesicles in the synthesis reaction results in
the formation of functional proteoliposomes which can be used as
vectors in the direct delivery of the membrane protein into
mammalian cell lines.
RESULTS
In vitro expression of truncated gp91
phox
An analysis of the prediction of the putative hydrophobic domains
of gp91
phox protein has been carried out through the use of
different programs (Sosui, TMHMM, TMpred and TopPred). An
alignment of the deduced transmembrane domains from these
programs with the structural model published by Taylor [17]
identified 6 hydrophobic domains which differ by 1 to 10 amino
acids, and 3 extracellular loops (Figure 1). Analysis of gp91
phox
transmembrane domains by mass spectrometry has provided
a more precise location of these transmembrane regions.
Therefore, in this study all the generated gp91
phox truncated
forms are based on the structural model from Taylor [17].
In general, the production of cytochrome b558 subunits gp91
phox
and p22
phox through classical over-expression systems have
resulted in low yields which are incompatible for further
biochemical studies [18]. Recent developments suggest that cell-
free expression systems represent an alternative to classical in vivo
expression. In order to decipher the molecular mechanisms
involved in the activity of human NADPH oxidase, we generated
five truncated forms of gp91
phox. Each construct contains
a histidine tag located either at the N- or at the C-terminus part
of the protein (Figure 2A). These truncated gp91
phox proteins were
first cloned into vectors dedicated to a prokaryotic expression
system and then synthesized in vitro by using a transcription-
translation system using an E. coli lysate.
We first set up the conditions for expressing each construct in
the presence or absence of chaperones or detergents. As an initial
validation, the expression of these ten truncated proteins was
analyzed by western blotting using an anti-his antibody (Figure 2B).
Similar results were obtained with a gp91
phox specific antibody
(data not shown). Interestingly, the expression pattern of each
construct depends on different parameters. Using the standard
conditions, all the truncated gp91
phox proteins are expressed but at
variable levels, as detected by western blotting (Figure 2B). The
position of the histidine tag may have a critical effect by decreasing
(e.g. gp91
phox 90-C) or by inhibiting (e.g. gp91
phox 233-C) the
expression of the truncated gp91
phox proteins (Figure 2B). Our
results suggested that the N-terminal hexa-histidine tag improves
Figure 1. Alignment of predicted hydrophobic domains of gp91
phox. This schema summarizes the different prediction of topology for gp91
phox by
using different programs (Sosui, TMHMM, TMpred and TopPred) or the model published by Taylor et al [17].
doi:10.1371/journal.pone.0000856.g001
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providing a better folding state of the expressed proteins.
We next studied the effect of non-ionic (n-dodecyl b-D-maltoside,
n-octyl b-D-glucopyranoside, n-thiooctyl b-D-glucopyranoside,
Nonidet P40) and zwitterionic (Chaps) detergents on the expression
of gp91
phox truncated forms. These detergents were selected as they
are mild, relatively non-denaturing and are compatible with in vitro
expression systems as they have no inhibitory effects on the
expression of membrane proteins. They were all tested at their
critical micellar concentration (CMC), except for Nonidet P40
(NP40), which was 100 times more concentrated than the usual
CMC (0.05 mM). Interestingly, these detergents displayed various
effects on protein expression. For example, Chaps and b-OG have
a strong negative effect on the expression of the gp91
phox truncated
forms, except for constructs gp91
phox 221-C with b-OG and
gp91
phox 221-C, gp91
phox 233-N and 233-C, gp91
phox 285-N with
Chaps (Figure 2B). These two compounds decreased the expression
of gp91
phox 221-N, but were compatible with the expression of
gp91
phox 221-C(Figure 2B). In contrast, NP40, Thio-OG and DDM
enhanced the expression levels for most of the gp91
phox truncated
forms, with a stronger effect on the constructs containing a hexa-
histidine at the N-terminal part of the protein (Figure 2B). These
Figure 2. Expression of truncated gp91
phox proteins. (A) Schematic representation of the phagocyte NADPH oxydase and truncated forms gp91
phox
expressed in a bacterial cell-free translation system. Gp91
phox full-length (FL) is presented at the top of the diagram: transmembrane domains are
shown in black. FAD and NADPH binding-sites are represented in red and pink respectively. Truncated gp91
phox were designed with a his-tag located
either at the N or at the C terminal part of the protein. (B) Analysis of the expression of the ten gp91
phox truncated proteins by western blot using
a monoclonal antibody anti-his.
doi:10.1371/journal.pone.0000856.g002
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with the synthesis of protein in a cell-free expression system, and that
this may result in an enhancement of protein synthesis.
The effect of the histidine tag position on protein synthesis was
also studied in the presence or absence of detergents or various
compounds. Interestingly, when the histidine tag is attached to the
N-terminal part of the protein, all the gp91
phox truncated forms
were synthesized, except in the presence of b-OG and Chaps
(Figure 2B). The other compounds (GroE and GSH/GSSG) had
no effect on the expression of the truncated forms, except for
constructs gp91
phox 90-N, 195-N and 233-C (Figure 2B). These
data indicate that the levels of expression of gp91
phox truncated
forms in a cell-free system depend on both the tag position and the
detergent. However, there is no clear rule to determine whether
a mammalian membrane protein will be expressed or not in a high
yield within this optimized cell-free expression system.
Based on these results, we sought to determine whether the
truncated gp91
phox proteins could be expressed under a soluble
form, as this form is usually considered to possess a ‘‘native-like’’
conformation. The solubility tests are summarized in Figure 3A.
Solubilization depends on a combination of three different factors:
(1) the structural properties of the membrane protein, (2) the
position of the tag (gp91
phox 233-N vs. -C or gp91
phox 221-N vs.
-C) and (3) the detergent by itself (DDM for gp91
phox 221-N/-C or
Chaps for gp91
phox 233-N/-C). Using the standard conditions of
the cell-free expression system, the gp91
phox truncated proteins
were expressed as precipitates (data not shown). All the proteins
were produced in a soluble form using DDM, except for the
gp91
phox 233 proteins which were solubilized in the presence of
Chaps. Whichever compound was added, the solubility of
gp91
phox 90-N protein remained too low to be used for further
experiments.
Figure 3. Solubility and activity of gp91
phox recombinant proteins. (A) Optimization of the solubility of the gp91
phox truncated proteins by western
blot using a monoclonal antibody anti-his. (B) Diaphorase assay of purified soluble truncated gp91
phox proteins using NBT or INT as electron acceptor.
Results were expressed as moles of NBT or INT reduced/min/mol gp91
phox truncated forms. Results are expressed as the average of at least two
experiments6SD.
doi:10.1371/journal.pone.0000856.g003
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phox
In order to investigate the functional response of the soluble
truncated gp91
phox proteins, it was necessary to determine whether
these proteins are able to transfer electrons like the native
cytochrome b558 purified from neutrophils [7]. Previous studies have
shown that the glycosylation of gp91
phox protein is not required for
its enzymatic activity [19]. However, the production of mammalian
membrane protein in an E.coli cell-free expression system results in
a non-glycosylated protein. To quantify the electron transfer from
NADPH to FAD, we used two different electron acceptors:
NitroBlueTetrazolium (NBT), the most commonly used electron
acceptor, or IodoNitroTetrazolium (INT), which has been shown to
specifically accept electrons from FAD [20]. Furthermore, the
existence of a diaphorase activity in the truncated gp91
phox proteins
would be an indicator of their correct folding status.
In order to obtain enough soluble proteins for the functional
assay, we over-expressed truncated gp91
phox proteins in large scale
reactions using the optimized conditions determined in Figure 3A
(Supplementary Figure S1), followed by purification onto affinity
chromatography. The soluble gp91
phox proteins were tested for
their diaphorase activity, and for each assay 10 pmoles of purified
soluble protein were used. None of the truncated proteins tested
exhibited activity in the absence of cytosolic regulatory proteins
(p47
phox, p67
phox, p40
phox and Rac; data not shown). By
incubating the recombinant proteins with neutrophil cytosol and
an optimum concentration of arachidonic acid (AA) for 10 min-
utes at 25uC, we were able to activate the recombinant proteins
and to observe NADPH-dependent diaphorase activity.
The results for gp91
phox 195-N, gp91
phox 221-C, gp91
phox 233-
N and gp91
phox 285-N proteins are represented in Figure 3B.
Their specific values of activity were 3, 6.1, 3.5 and 2.9 mol/min/
mol for NBT and 4.2, 7.2, 5.3 and 3.8 mol/min/mol for INT
respectively. The gp91
phox 221-C protein showed an overall
reductase activity which was higher for both NBT and INT
compared to the other proteins (Figure 3B). For all the proteins,
a diaphorase assay using INT as electron acceptor gave a higher
turnover rate compared to the NBT values (Figure 3B). This could
be explained by its higher specificity of electrons released by the
FAD during the classical electron transfer pathway [21].
To confirm that the diaphorase activity measured with
truncated gp91
phox proteins was directly dependent on the
presence of cytosolic regulatory factors, we performed the same
experiment with a cytosolic fraction isolated from control or
p67
phox-deficient EBV-B lymphocytes. First, the diaphorase
activity of native cytochrome b558 purified from neutrophils was
analyzed. As expected, the electron transfer was correlated to the
presence of cytosolic factors p67
phox, p47
phox and Rac as shown by
the absence of activity measured with p67
phox-deficient cytosol or
without cytosol (Figure 4A). The diaphorase activity was in the
range of 500–600 mol/min/mol heme b, depending on the
electron acceptor used (INT or NBT). Then, the activity of the
gp91
phox 221-C was determined after incubation with control or
deficient B lymphocyte cytosol, and arachidonic acid. The
diaphorase activity was in the range of 5 mol/min/mol gp91
phox
221-C with the control cytosol and was strongly and significantly
decreased in presence of p67phox-deficient cytosol (,0.9 mol/
min/mol gp91
phox 221-C, Figure 4B).
Taken together, these results suggested a direct interaction
between the cytosolic factors (p47
phox,p 6 7
phox,p 4 0
phox and Rac)
and the recombinant soluble proteins, indicating an assembly of
these factors and the truncated proteins as earlier described for the
native cytochrome b558 during the activation of the NADPH oxidase
complex [1]. Moreover, all the recombinant truncated gp91
phox
proteinstested weresolubleand showedaspecificenzymaticactivity,
confirming that they are in a correct and active folding state.
Expression of truncated gp91
phox in the presence of
lipids
The acquisition of liposomes containing active membrane proteins
is a useful tool in the study of their biochemical properties.
Moreover, functional gp91
phox proteoliposomes may represent an
attractive delivery system for complementing NADPH activity in
the neutrophils of CGD patients.
In this study, we used natural lipids from spinach thylakoids.
These are anionic lipids mainly composed of diacylglycerol
derivatives. Usually, to obtain membrane protein inserted into
a lipid vesicle, 2 steps are required: (1) extraction/solubilization/
purification of the membrane protein from its natural source or
from the over-expression system (i.e. inclusion bodies in E.coli)b y
using detergents or chaotropic agents (urea or guanidine), and (2)
reconstitution into liposomes after refolding [12]. The originality
of our approach results in the production of the proteoliposomes in
Figure 4. Specificity of the diaphorase activity measured with
gp91
phox recombinant proteins. (A) Diaphorase activity measured
with cytochrome b558 purified from neutrophils (10 pmol) in presence
o fc y t o s o lf r o mn o r m a l( N )o rp 6 7
phox deficient (p67
0)E B VB
lymphocytes using NBT (black bars) or INT (open bars) as electron
acceptor. (B) Diaphorase activity measured with the gp91
phox 221-C
protein (10 pmol) in presence of cytosol from normal (N) or p67
phox
deficient (p67
0) EBV B lymphocytes using INT (open bars) as electron
acceptor. Results are expressed as the mean activity of three
experiments6SD. * indicates results significantly different (P,0.05)
from the control performed in presence of normal cytosol.
doi:10.1371/journal.pone.0000856.g004
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mixture during the synthesis.
Firstly, our goal was to determine whether truncated gp91
phox
proteins could be expressed and integrated into natural lipids. We
tested the expression of three membrane proteins, gp91
phox 221-C,
gp91
phox 195-N and gp91
phox 90-N containing respectively 1, 2
and 4 transmembrane domains in the presence of thylakoid lipids.
For the gp91
phox 221-C and gp91
phox 195-N proteins, a modula-
tion of the expression depending on the amount of lipids added
during the synthesis was observed. This effect is negligible in the
presence of low concentrations of lipids (#2.5 mg/ml), but an
inhibition of the expression can be observed in the presence of
higher concentrations of lipids ($4 mg/ml, Figure 5A). In-
terestingly, the expression of gp91
phox 90-N protein in the same
conditions showed the opposite effect (Figure 5A). The addition of
lipids (up to 2.5 mg/ml) enhanced its expression, and higher
concentrations (.2.5 mg/ml) resulted in a slight inhibition
compared to 2.5 mg/ml of lipids (Figure 5A). Based on these
results, we next performed large-scale expression reactions for the
construct gp91
phox 221-C in the presence of 2.5 mg/ml of lipids.
These proteoliposomes can be quickly and easily purified by
sucrose gradient centrifugation, resulting in a purified protein
which is largely integrated into the lipids vesicles (data not shown).
Diaphorase assay of gp91
phox 221-C
proteoliposomes
In order to evaluate the effect of the integration into natural lipids
on the capacity to transfer electrons of the gp91
phox 221-C
proteins, we used purified recombinant proteoliposomes contain-
ing gp91
phox 221-C protein and assessed its reductase activity as
described for the soluble gp91
phox 221-C protein (Figure 3B).
Interestingly, truncated gp91
phox 221-C proteins integrated into
natural lipid vesicles exhibit NADPH- and FAD-dependent
activity that did not require the addition of cytosolic factors and
AA (Figure 5B, without activation). As already described by
Koshkin [22,23], the phospholipid environment of relipidated
gp91
phox protein has a critical influence on its folding status and on
its affinity to bind co-factors such as FAD, leading to a self-active
gp91
phox protein that only requires NADPH and FAD. This basal
activity of gp91
phox 221-C protein in the presence of the 2 co-
factors was 7.8 mol of NBT reduced/min/mol of gp91
phox 221-C
proteoliposomes and 5.5 mol of INT reduced/min/mol of
gp91
phox 221-C proteoliposomes. These values were comparable
to those obtained for the gp91
phox 221-C protein expressed in the
presence of detergent and activated by cytosolic factors and AA
(6.1 and 7.2 mol/min/mol for NBT and INT respectively,
Figure 3B). This means that the gp91
phox 221-C protein embedded
into natural lipids is folded in a more active conformation in
comparison to the detergent-soluble protein.
When10pmolesofrecombinantgp91
phox221-Cproteoliposomes
were incubated for 10 minutes with neutrophil cytosol (containing
p47
phox,p 6 7
phox,p 4 0
phox and Rac) and AA at 25uC, reductase
activity was enhanced by a seven fold increase for NBT and ten fold
for INT (53 mol/min/mol for both NBT and INT, Figure 5B
activated). Taken together, these results confirmed that the
recombinant truncated gp91
phox 221-C protein was able to display
a partial diaphorase activity when embedded into natural lipids and
an increased activity after activation by cytosolic partners and AA.
Transduction of active proteoliposomes gp91
phox
221-C into living cells
To test the capacity of the recombinant proteoliposomes to deliver
active gp91
phox 221-C protein, we used a human carcinoma cell
line HCT116 which is negative for gp91
phox messenger and
proteins (data not shown).
The cells were incubated with gp91
phox 221-C proteoliposomes
for 8 hours. The uptake of exogenous gp91
phox 221-C protein by
the cells was detected by imunocytochemistry staining using an
anti-his antibody (Figure 5C). Only cells incubated with proteo-
liposomes gp91
phox 221-C were positive for imunocytochemistry
staining with a punctuated signal surrounding the cells (Figure 5C).
To confirm the cellular integration of the exogenous gp91
phox
221-C protein into the plasma membrane a set of experiments has
been performed using freshly produced gp91
phox 221-C proteo-
liposomes. HeLa cells were incubated for 8 hours either with
gp91
phox 221-C proteoliposomes or empty liposomes or soluble
gp91
phox 221-C. The subcellular localization of the exogenous
gp91
phox 221-C protein in the cells was detected by imunocy-
tochemistry staining using an anti-gp91
phox antibody (54.1, in red)
and an anti-Clathrin light chain subunits (sc-28276, in green).
After fixation, cells were analyzed using confocal microscopy
(Figure 5D). Cells incubated with the soluble protein were
permeabilized or not with saponin to check for possible external
binding. A red punctuated signal can be observed only with cells
incubated with gp91
phox 221-C proteoliposomes illustrating that
our results are reproducible and that the delivery is specifically due
to the liposome carrier (Figure 5 C and 5D). Furthermore, the
orthogonal sections show that the exogenous gp91
phox 221-C
protein is localized into the same z sections as the clathrin clearly
indicating that the protein is integrated into the plasma membrane
(Figure 5D, [24]).
Theuseofliposomesasadeliverytoolallowedthereleaseofactive
membrane protein directly into the plasma membrane of cells.
Diaphorase assay of gp91
phox 90-N proteoliposomes
In order to improve the system of production of mammalian
membrane proteins and to further explore the effects of the
gp91
phox protein, we produced the gp91
phox 90-N protein which
contains 4 transmembrane domains in the presence of natural
liposomes. As previously found for gp91
phox 90-N (Figure 5A), the
optimal amount of lipids required for its synthesis was 2.5mg/ml.
Interestingly, as for the gp91
phox 221-C proteins, the gp91
phox
90-N proteins embedded into natural lipid exhibited an intrinsic
activity without cytosolic factors and AA (Figure 6A, without
activation, 13.5 mol/min/mol for NBT reduction and 14 mol/
min/mol for INT reduction). These values were slightly higher
than for the gp91
phox 221-C proteoliposomes (Figure 5B), but the
addition of cytosolic extract and AA enhanced the activity of
recombinant gp91
phox 90-N to the similar values of gp91phox 221-
C proteoliposomes, indicating a fully active enzyme (54 and
53 mol/min/mol for NBT and INT respectively, Figure 6A).
Embedded into natural lipids, recombinant truncated gp91
phox
proteins displayed basal activity and a maximum turnover upon
activation (Figures 5B and 6A).
Transduction of active proteoliposomes gp91
phox
90-N into living cells
In order to examine the delivery of active mammalian membrane
protein using liposomes as carriers, we used a human carcinoma
cell line HeLa which is negative for gp91
phox proteins (data not
shown) so as to exclude cellular specificity of the delivery.
To improve this delivery system and to follow the destiny of
exogenous protein, we observed the subcellular distribution of
transduced gp91
phox 90-N protein in HeLa cells after 8 and
24 hours by immunocytochemistry using either an anti-his
antibody (Figure 6B) or an anti-gp91
phox antibody (Figure 6C).
Active NOX2 Proteoliposomes
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phox 90-N proteolipo-
somes were positive for immunocytochemistry staining with both
antibodies (Figures 6B and 6C). The higher background for the
anti-gp91
phox antibody (Figure 6C) could be explained by its
cross-reactivity with GRP 58 protein [25]. After 8 hours, the
punctuated signal surrounding the cells indicated a plasma
membrane localization (Figures 6B and 6C) for the delivered
gp91
phox 90-N proteins and after 24 hours, the proteins remained
detectable and localized to the plasma membrane of the cells
(Figures 6B and 6C).
The delivery of recombinant mammalian membrane proteins
into living cells using liposomes as a vector appears to be a powerful
system in the targeting of deficient cells (Figures 5C, 5D, 6B and
6C).
Figure 5. gp91
phox 221-C proteoliposomes. (A) Expression of membrane protein in presence of lipids analyzed by western blot using a monoclonal
antibody anti-his. (B) Diaphoraseassay ofpurifiedproteoliposomes gp91
phox221-C using NBTor INT as electron acceptor, n$2.(C) Deliverygp91
phox221-
C with proteoliposomes in HCT116 cells after 8 hours of incubation. As a negative control, cells were incubated with the same amount (0.5 mg) of empty
liposomes. The proteins were detected by fluorescence microscopy using a monoclonal anti-his antibody. (D) Confocal analysis of the distribution of
gp91
phox221-CproteindeliveredwithproteoliposomesinHeLacellsafter8 hoursofincubation.Asanegativecontrol,cellswereincubatedwith0.5 mgof
empty liposomes or 0.5 mgo fs o l u b l eg p 9 1
phox 221-C. Cells were labelled for the exogenous protein using an anti-gp91
phox antibody (Red) and for the
endogenousClathrin(Green).ThecellswereexaminedunderaZeissLSM510(NLO)laserconfocalmicroscope.Theimageplanewaschosentobenearthe
equator of the cell body and nucleus. (E) Higher magnification of the white boxed area in (D) with the respective xz projections.
doi:10.1371/journal.pone.0000856.g005
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The study of functional membrane proteins remains a challenging
task, regardless of the fact that important progress has recently
been made in the isolation of eukaryotic membrane proteins from
natural sources or the production of membrane proteins in
heterologous expression systems [26]. The failure to produce
recombinant eukaryotic membrane proteins is mainly due to
a misfolding and rapid degradation of the over-expressed
membrane proteins. Moreover, low yields and cellular toxicity
can account for the difficulty in producing membrane proteins.
Recent studies on the synthesis of mammalian membrane proteins
in different optimized expression systems have been explored in
order to produce large amounts of recombinant proteins for
functional and structural studies [27–30]. However, expression in
these systems often results in the targeting of the membrane
proteins to the inclusion bodies or to the membrane of the host
cells, thus rendering their subsequent study difficult. Cell-free
expression systems represent an excellent alternative to the
classical in vivo over-expression systems [13]. These have already
been used for the production of membrane proteins from E. coli
[14,31,32] or from eukaryotic sources [15,16].
The gp91
phox protein is a transmembrane glycosylated hemo-
protein. It is the redox-subunit of cytochrome b558 and the catalytic
core of the phagocyte NADPH oxidase. The lack of gp91
phox
causes an X-linked chronic granulomatous disease (CGD), a rare
genetic disorder characterized by severe and recurrent infections
due to the failure of O2
2-generating NADPH oxidase and the
absence of reactive oxygen species. Different approaches have been
used to study the NADPH oxidase complex, including monoclonal
antibodies [17,33], isolation and purification of the complex from
neutrophils [7,34] and the expression of deletion mutants of the
gp91
phox protein [6,35] or of the p22
phox protein [8]. These
methods have provided vital information about the regulation of
this enzymatic complex through the identification of new
regulatory proteins [34], the description of domains of interaction
between its two subunits [8], the modification of the conformation
of gp91
phox [33] and topological information regarding the
components of the NADPH complex [17].
In this study we have developed a new method for producing
fully active recombinant truncated gp91
phox proteins containing
up to 4 transmembrane domains (Figures 2A and 2B). We show
that recombinant gp91
phox proteins are solubilized by non-ionic or
zwitterionic detergents and that they exhibit reductase activities in
the absence of p22
phox protein. Recent studies reported that the C-
terminal part of the protein (aa 221 to 570) is responsible for
electron transfer from NADPH to FAD [6,36]. However,
stimulation of the reductase activities of these constructs appears
to depend either on the activation domain of p67
phox and Rac or
on the carboxyl-terminal truncated p67
phox fused with Rac [5].
Our finding shows that soluble gp91
phox 221-C displays an
NADPH- and a p67
phox-dependent diaphorase activity (Figure 3B
and 4B) identical to that described by Nisimoto using truncated
forms of gp91
phox over-expressed as inclusion bodies in E.coli [6].
These data confirm the specific role of the cytosolic regulatory phox
factors in the electron transfer activation in the gp91
phox truncated
form and led us to conclude that our optimized cell-free expression
system represents a new alternative to obtaining active truncated
gp91
phox recombinant derivatives.
Our recombinant model also supports previous works reporting
that N-glycosylation on three Asn residues [Asn132, Asn149 and
Asn240; 4] of the wild type gp91
phox protein are not required for
the production of superoxide anions [19]. Although we cannot
exclude the possibility that glycosylation may be involved in
cytochrome b558 stability in neutrophils, all the recombinant
proteins produced by the cell-free expression system are not
glycosylated, but display diaphorase activities.
Taken together, these results demonstrate that our optimized
cell-free expression system represents a new alternative for the
generation of active truncated gp91
phox proteins. These derivatives
could be used as molecular probes to further investigate the
interaction between gp91
phox and p22
phox and the subsequent
conformation states of cytochrome b558 at rest and upon activation
of NADPH oxidase. Furthermore, this original recombinant
Figure 6. gp91
phox 90-N proteoliposomes. (A) Diaphorase assay of
purified proteoliposomes gp91phox 90-N using NBT or INT as electron
acceptor, n$2. Cellular uptake of gp91
phox 90-N proteins delivered with
proteoliposomes in HeLa cells after 8 or 24 hours of incubation. The
proteins were detected by fluorescence microscopy using a monoclonal
anti-his antibody (B) or a monoclonal anti-gp91
phox antibody (C).
doi:10.1371/journal.pone.0000856.g006
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gp91
phox, mainly Nox1 and Nox4 of the Nox family [37].
Previous studies of Koshkin and Pick showed an intrinsic
activity of the purified cytochrome b558 from neutrophils after
integration into lipids without the requirement of any activation
[22,23], implying that the lipid environment plays a crucial role in
the activity and the conformation of proteins. An interesting
feature of the cell-free expression system is its compatibility with
natural lipid vesicles. We have demonstrated that the addition of
liposomes into the reaction mixture allows direct formation of
active proteoliposomes containing truncated gp91
phox protein or
membrane proteins from various origins (Liguori et al., submitted).
We showed that gp91
phox 221-C proteoliposomes display similar
diaphorase activity as the soluble protein, even in absence of
cytosolic factors or anionic amphiphile (7.8 mol/min/mol for
gp91
phox 221-C proteoliposomes and 6.1 mol/min/mol for
soluble gp91
phox 221-C). Moreover, the diaphorase activity of
gp91
phox 221-C proteoliposomes can be enhanced 7 to 10 fold by
the addition of cytosolic partners and AA, leading to a better
activation of the protein. Furthermore, similar results have been
obtained with gp91
phox 90-N proteoliposomes. These results
suggest a ‘‘native-like’’ conformation for these gp91
phox constructs
that was directly dependent on the lipid environment. This, to our
knowledge, is the first demonstration of an active recombinant
gp91
phox protein with four transmembrane domains directly
integrated into lipids in the absence of the p22
phox protein.
Recently, a fully active NADPH oxidase complex was isolated
onto an affinity matrix and in the absence of lipids. The
constitutive activity of the isolated complex suggested a change
of cytochrome b558 conformation from an inactive to an active
state [7]. Moreover, prenylated p67
phox-rac1 chimera were shown
to activate membrane cytochrome b558 in vitro in the absence of lipids
or amphiphil reagent [38]. However, our findings point to the
development of a recombinant model of neutrophil-like NADPH
oxidase which allows the direct production of active and ‘‘native-
like’’ membrane gp91
phox that is qualitatively similar to that of
purified protein from neutrophils. Further structural data will shed
light on the mechanisms of diaphorase activation of recombinant
gp91
phox constructs in the absence or presence of lipids.
Data presented here provide conclusive results on the capacity
of the optimized cell-free expression system to produce fully active
proteoliposomes in a one-step reaction. Liposomes are now widely
used for the delivery of various therapeutic molecules such as
antibodies [11], nucleic acids [39], peptides [40] and antifungal
[41] or anticancer drugs [42]. These molecules can be located
either in the aqueous compartment, if soluble, or embedded into
the bilayer for hydrophobic compounds. Moreover, various
liposomal vesicles containing pharmaceutical agents have been
developed to sustain their therapeutic actions in vivo by a prolonged
half-life circulation, a reduced cytotoxicity and an improved
cellular and tissue targeting [43].
One of the current challenges in therapy is to develop new
strategies in the efficient treatment of disease. Encouraging results
have recently been obtained using gene therapy to treat CGD
[10]. However, even if gene therapy appears to be a promising
method of treatment of rare diseases, its efficiency needs to be
improved, and a number of major problems inherent to this
technology remain to be solved, such as immunogenic responses
against the vector, low specificity of cells expressing the protein
and the random insertion of DNA into the genome of cells [44].
Therefore, an alternative or a complementary approach to gene
therapy needs to be developed.
In this paper, we report the development of a new method to
produce recombinant proteoliposomes containing membrane
protein in a one-step reaction, and we demonstrate that these
proteoliposomes can be used as carriers for delivering membrane
proteins. We evaluate the ability of proteoliposomes to exhibit
diaphorase activity in in vitro assays (Figures 5B and 6A) and to
efficiently deliver truncated gp91
phox protein into cells targeting
their plasma membrane (Figures 5C, 5D, 6B and 6C). Therefore,
we demonstrated the ‘‘proof of concept’’ that the active embedded
protein can be directly delivered to the plasma membrane of
different cell lines, and we demonstrated that our proteoliposomes
may represent an original approach for protein therapy. However,
production by the cell-free expression system of a fully functional
cytochrome b558 containing two hemes remains a challenge. The
incorporation of hemin in the cell-free expression medium was first
tested to evaluate the feasibility to express heme-bound protein with
this expression system. Preliminary results indicate that concentra-
tionsof heminbelow 1.6 mM donot interferewith thetranscription/
translation process suggesting that the cell-free expression system
could be useful to produce recombinant cytochrome b558.
MATERIALS AND METHODS
Materials
All the chemicals were from Sigma-Aldrich and the detergents from
Calbiochem. Medium for cell culture were from Invitrogen-Gibco.
Truncated gp91
phox
The different versions of gp91
phox were obtained by PCR. The
forward primers (
59GGAATTCCATATGGTTCGAAGACAAC-
TGGACAGG
39 for gp91
phox 90,
59GGAATTCCATATGAAAA-
CCATCCGGAGGTCTTAC
39 for gp91
phox 195,
59GGAATTC-
CATATGATCCATGGAGCTGAACGAA
39 for gp91
phox 221,
59GGAATTCCATATGGCAGAGAGTTTGGCTGTG
39 for
gp91
phox 233 and
59GGAATTCCATATGTTTTGGCGATCT-
CAACAGA
39 for gp91
phox 285) were designed to introduce a NdeI
site (shown in boldface). The reverse primers (
59GCGTTACTC-
GAGTCATGGAAGAGACAAGTTAGAAG
39 for the N-
terminal position of the his-tag or
59GCGTTACTCGAG-
GAAGTTTTCCTTGTTGAAAATG
39 for the C-terminal posi-
tion of the his-tag) were designed to introduce a XhoI site (shown
in boldface) and a stop codon for the N-terminal position of the
his-tag (underlined). The truncated gp91
phox were directly cloned
in pIVEX 2.3MCS and in pIVEX 2.4NdeI vectors (Roche
Applied Science).
Cell-free expression of gp91
phox
Expression test for each protein was performed using the RTS
TM
HY100 (Roche Applied Science) according to the manufacturer’s
instructions. We tested different compounds to enhance the
expression under soluble form (i.e. ‘‘native-like’’ conformation):
GroE chaperone, GSH/GSSG (0.01 mM/0.4 mM), Nonidet P40
(NP40, 5 mM), b-OG (n-Octyl-b-D-glucopyranoside, 25 mM),
Thio-OG (n-Octyl-b-D-thioglycopyranoside, 9 mM), DDM (n-
Dodecyl-b-D-maltoside, 0,1 mM), CHAPS (3-[(3-cholamidopro-
pyl)-dimethylammonio]propanesulfonate, 10 mM) or liposomes at
different concentration (from 1 mg/ml up to 5 mg/ml). Lipo-
somes are obtained by evaporation of CHCl3/MeOH from the
lipid preparation (SpeedVac System, Thermo Savant) and
resuspension of the lipids in DEPC water. Sonication (3 times
for 1 minute on ice, Branson Sonic power, Smithkline Company
Brentford, Middlesex, UK) and filtration through a 0.22 mm filter
leads to liposomes constitution. The reactions were performed
during 15 h at 30uC with 180rpm shaking in the Proteomaster
TM
(Roche Applied Science). The solubility was assayed by centrifu-
gation (30 minutes, 21400 g, 4uC) using a Sigma 2K15 centrifuge.
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when expressed with liposomes) and the solubility was evaluated
by densitometry analysis of the western blot using ImageJ
programme (NIH, USA). For scale-up experiments, RTS
TM
HY500 ProteoMaster from Roche Applied Science was used
during 48 hours at 20uC with 990rpm shaking.
Purification of the soluble proteins by IMAC
The soluble fraction of the reaction was equilibrated by the addition
of 4 column volumes (CV) of buffer A (Na-phosphate 50 mM
pH 7+500 mM NaCl+Glycerol 15%+DDM 0,1 mM+Complet
EDTA free) and then loaded, at least 10 times, onto a column
containing500 mlofTa lo n
TMresin(BDBiosciencesClonetech),pre-
equilibrated with 20 CV of buffer A. The column was then washed
extensively with 20 CV of buffer A+10 mM imidazol. The protein
was eluted with 4 CV of buffer A+250 mM imidazol.
Proteoliposomes purification
After production, the mixtures are centrifuged at 13000 g, 20 min
at 4uC, the supernatant discarded and the pellet resuspended in
1 ml Tris 50 mM, pH 7.2. The resuspended pellet was loaded on
a 3 steps discontinuous sucrose gradient (60%, 25% and 10%)
prepared in Tris 50 mM, pH 7.2. The sample is loaded between
60% layer (6 ml) and 25% layer (6 ml). 2 ml of 10% sucrose fulfils
the gradient. After ultracentrifugation (1 hour at 200000g at 4uC),
fractions of 1 ml were collected until the bottom of the gradient
and analyzed by western blotting and silver staining.
Lymphoid Cell Line and Neutrophils
Citrate-sterile venous blood was drawn from either healthy
patients or a CGD patient with previously characterized CGD
AR p67
0 after informed consent. Neutrophils and B lymphocytes
were isolated by Ficoll-Hypaque density gradient centrifugation
[7]. Lymphocytes were collected at the Ficoll surface and infected
with the B95-8 strain of Epstein-Barr virus (EBV) as described
previously [7]. The EBV-B lymphocyte cell lines were kept in
culture using RPMI 1640 supplemented with 10% fetal calf serum,
2 mM L-glutamine, and 2 mg/mL Ciflox, at 37uC under a 5%
CO2 atmosphere. Neutrophils were collected in the pellet after
red-cell hypotonic lysis [7]. Crude membrane and cytosol fractions
from both cell types were prepared as reported previously [7].
Cytochrome b558 purification
Cytochrome b558 was purified from the plasma membranes of 10
10
PMA-stimulated neutrophils and relipidated with L-a-phosphati-
dylcholine II-S as reported [19].
Diaphorase assay in cell-free system
Electron transfer activity was measured in vitro using previously
described protocols [45]. Purified proteins (gp91
phox truncated forms
or neutrophil cytochrome b558), 10 pmoles, were incubated with
FAD (10 mM), MgCl2 (5 mM), GTPcs( 4 0mM), 300 mgo fc y t o s o l
from either human neutrophils or EBV-B lymphocytes (control or
deficient in p67
phox), and an optimum amount of AA (20 mM in
EtOH) in PBS. After incubation for 10 min at 25uC, the reaction
was initiated by the addition of NADPH (15 mM) in the presence of
NBT (NitroBlue Tetrazolium) or INT (IodoNitro Tetrazolium) and
the reduction of these compounds was followed during 30 minutes
(at 595nm for NBT, e595nm=12.6mM
21.cm
21 or at 500 nm for
INT, e500nm=11mM
21.cm
21). For the proteoliposomes, the assay
was performed with or without sonication.
Cell Culture
HCT116 cells were cultured in McCoy’s 5A medium supplemen-
ted with 10% heat-inactivated fetal bovine serum. HeLa cells were
cultured in D-MEM medium supplemented with 10% heat-
inactivated fetal bovine serum. For immunocytochemystry experi-
ments, cells were cultured in eight-well slide chambers (Nalgen
Nunc International) and treated with purified gp91
phox proteoli-
posomes or soluble gp91
phox protein at final concentration of
0.5 mg per 1610
6 cells and incubated for 8 or 24 hours before
imunocytochemistry.
Imunocytochemistry
After incubation, cells were washed 2 times 5 minutes in PBS and
fixed for 10 minutes in PFA 4% at 25uC. They were permeabi-
lized 10 minutes in PBS, saponin 0.1% at 25uC, followed by
1 hour incubation at 25uC in blocking solution (PBS, 0.1%
saponin, milk 5%) and over-night incubation at 4uC with primary
monoclonal antibody (54.1 or anti-his, Euromedex clone 1DM-
1H7) diluted at 1:1000 in blocking solution. After 3 washes in PBS
for 5 minutes cells are incubated with a secondary antibody in
blocking solution at 1:1000 during 1 hour at 25uC (goat anti-
mouse Alexa-fluor 546, Molecular Probes). For confocal analysis,
cells were incubated 5 hours at 25uC with Clathrin antibody
(Clathrin LCA (H-55): sc-28276; Santa Cruz Biotechnology, Inc)
diluted at 1:500 in blocking solution, washed 3 times in PBS for
5 minutes cells and incubated with a secondary antibody in
blocking solution at 1:1000 during 1 hour at 25uC (goat anti-
rabbit Alexa-fluor 488, Molecular Probes). Cells were washed 3
times 5 minute with PBS and nuclei were stained with Hoechst
33258 (1:2000) during 5 minutes at 25uC, washed again and then
mounted. Samples were analyzed with an inverted Nikon Eclipse
TE2000-E equipped with epifilters for the different fluorochromes
using a 606immersion objective or under a Zeiss LSM510 (NLO)
laser confocal microscope.
SUPPORTING INFORMATION
Figure S1 Example of solubility after scale-up production
detected by Coomassie blue staining and by western blotting.
The solubility of gp91
phox 285-N and gp91
phox 221-C proteins was
analyzed, after scale-up synthesis, by Coomassie blue staining and
by western blotting using an anti-his antibody. For the gp91
phox
285-N protein, 15% of the produced protein was found in the
soluble fraction and for the gp91
phox 221-C protein, 26% of the
synthesized protein was recovered in the supernatant after
centrifugation. The levels of solubilization for the gp91
phox
195-N and gp91
phox 233-N proteins were comparable to those
of gp91
phox 285-N (data not shown).
Found at: doi:10.1371/journal.pone.0000856.s001 (2.31 MB TIF)
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